Processa (PCSA) Director Neal James Receives 62,221-Share RSU Award

What Happened Neal James, a director of Processa Pharmaceuticals, reported a grant of 62,221 restricted stock units (RSUs) on July 26, 2026. The Form 4 lists the acquisition price as $0.00 (award/derivative), so no cash changed hands; the RSUs vested upon grant but will not be distributed immediately per the award terms.

Key Details

• Transaction date: 2026-07-26; Form 4 filed 2026-07-28 (filed within the normal reporting window).
• Award: 62,221 RSUs recorded as a grant (derivative), price shown $0.00; total cash value reported $0 on the form.
• Shares owned after transaction: not specified in the provided filing excerpt.
• Footnotes of note:
  • F1: Each RSU converts to one common share but distribution is deferred until the earlier of termination, six months after grant, a change of control, or death.
  • F2: Describes separate stock option vesting schedules (not directly part of this RSU award).
  • F3: Amounts reflect a 1-for-25 reverse stock split effected Dec 17, 2025.
• Filing status: appears timely (filed two days after the report date).

Context This transaction is an equity award (compensation) rather than an open-market purchase or sale. Although the RSUs vested on grant, they are subject to distribution timing described in F1, so the director does not immediately receive tradable shares. Awards like this are common for directors and do not by themselves indicate a buy/sell signal.